amrubicin
Small moleculeexperimental
Amrubicin is an anthracycline used in the treatment of lung cancer. It is marketed in Japan since 2002 by Sumitomo under the brand name Calsed. — Wikipedia
Clinical trial activity
20 trials · 21 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
17
Phase 3
5
Phase 4
0
Earliest trial started May 1, 2004 (NCT00132054)
Timeline
Indications
Mechanism of action
- DNA topoisomerase II alphaINHIBITOR
TOP2A inhibitor
Intercalates into DNA and inhibits the activity of topoisomerase II, resulting in inhibition of DNA replication.
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O- Mol. weight
- 483.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1186894 ↗
- WikipediaAmrubicin ↗
- ChEMBLCHEMBL481958 ↗
Also known as
- (+)-(7s,9s)-9-acetyl-9-amino-7-((2-deoxy-beta-d-erythro-pentopyranosyl)oxy)-6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
- (7s,9s)-9-acetyl-9-amino-7-((2-deoxy-beta-d-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride
- amrubicin
- amrubicin
- amrubicin
- amrubicin
- amrubicin
- amrubicin
- amrubicin
- amrubicin hcl
- amrubicin hydrochloride
- amrubicin hydrochloride
- amrubicin hydrochloride
- amrubicin hydrochloride
- amrubicin hydrochloride
- sm 5887
- sm-5887
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03253068 | Phase 2 | Aug 1, 2017 | Kindai University, Merck, Wakayama Medical University |
| NCT02481830 | Phase 3 | Aug 1, 2015 | Bristol-Myers Squibb, Ono Pharmaceuticals |
| NCT01904253 | Phase 2 | Jul 1, 2013 | Nippon Medical School, Otsuka, University of Turin |
| NCT01259375 | Phase 2 | Sep 1, 2011 | University of Utah |
| NCT01355705 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2011 | Celgene, Stanford University |
| NCT01364727 | Phase 2 | Jun 1, 2011 | Celgene, Stanford University |
| NCT01331824 | Phase 2 | Feb 1, 2011 | Celgene, Icahn School of Medicine at Mount Sinai |
| NCT01207011 | Phase 3 | Oct 1, 2010 | Sumitomo Dainippon |
| NCT01033032 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2009 | Celgene, SCRI Development Innovations |
| NCT01076504 | Phase 2 | Dec 1, 2009 | Celgene, SCRI Development Innovations |
| NCT00915083 | Phase 1 | Jun 1, 2009 | Celgene |
| NCT00890955 | Phase 1 | Mar 1, 2009 | Celgene, Hoosier Cancer Research Network |
| NCT00660504 | Phase 3 | Apr 1, 2008 | Chinese Academy of Medical Sciences, Sumitomo |
| NCT00547651 | Phase 3 | Sep 1, 2007 | Celgene |
| NCT00388960 | Phase 2 | Nov 1, 2006 | Celgene, Royal Marsden Hospital NHS Trust |
| NCT00375193 | Phase 2 | Nov 1, 2006 | Celgene, Theradex |
| NCT00380835 | Phase 2 | Sep 26, 2006 | Celgene, Theradex |
| NCT00286169 | Phase 3 | Apr 1, 2006 | Sumitomo Dainippon |
| NCT00319969 | Phase 2 | Apr 1, 2006 | Celgene, Theradex |
| NCT00132054 | Phase 1 | May 1, 2004 | Japan Multinational Trial Organization, Kyoto University |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (21)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 12 | 6 | 3 | 2006 |
| Theradex | For profit | 3 | 0 | 1 | 2006 |
| SCRI Development Innovations | For profit | 2 | 2 | 1 | 2009 |
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2011 |
| Sumitomo Dainippon | For profit | 2 | 2 | 1 | 2006 |
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Japan Multinational Trial Organization | Academic/Hospital | 1 | 1 | 1 | 2004 |
| Kindai University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Kyoto University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| Nippon Medical School | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Ono Pharmaceuticals | For profit | 1 | 0 | 1 | 2015 |
| Otsuka | For profit | 1 | 1 | 1 | 2013 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Sumitomo | For profit | 1 | 1 | 1 | 2008 |
| University of Turin | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Utah | Academic/Hospital | 1 | 1 | 1 | 2011 |
21 organizations
Page 1 / 2